Literature DB >> 6112981

Calcium antagonists: definition and mode of action.

W G Nayler, P Poole-Wilson.   

Abstract

The term "calcium antagonist" has been used for more than a decade to describe a group of drugs whose negative inotropism is overcome by calcium. Because this term lacks specificity with respect to a precise mode of action, and implies a classical receptor-agonist-antagonist relationship, its continued use should be questioned. Drugs belonging to this group are verapamil, D600, nifedipine and diltiazem. They inhibit the slow inward current of the action potential and would more appropriately be called "slow channel inhibitors". The group is heterogenous and may have to be subclassified. The negative inotropism of these drugs can be attributed to a reduction of the slow calcium current. The function of most intracellular organelles is unaffected. Studies with radioactively labelled verapamil show tight binding to glycolipids or glycoproteins in the sarcolemma. Consequent change in the conformational state of the cell membrane could inhibit the slow calcium current. The ability of these drugs to protect heart muscle against the deleterious effects of ischaemia and reperfusion may reflect their negative inotropism, with consequent maintenance of tissue ATP above the levels needed to maintain intracellular Ca2+ homeostasis, rather than a direct inhibitory effect on calcium influx during ischaemia or on reperfusion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112981     DOI: 10.1007/bf01908159

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  62 in total

1.  Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium. III. Effects of the optical isomers on transmembrane action potentials.

Authors:  R Bayer; D Kalusche; R Kaufmann; R Mannhold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Slow Ca2+ and Na+ responses induced by isoproterenol and methylxanthines in isolated perfused guinea pig hearts exposed to elevated K+.

Authors:  J A Schneider; N Sperelakis
Journal:  J Mol Cell Cardiol       Date:  1975-04       Impact factor: 5.000

3.  Effects of calcium-antagonistic coronary vasodilators on myocardial contractility and membrane potentials.

Authors:  H Nabata
Journal:  Jpn J Pharmacol       Date:  1977-04

4.  The effect of beta-adrenoceptor and Ca2+ antagonist drugs on the hypoxia-induced increased in resting tension.

Authors:  W G Nayler; C E Yepez; P A Poole-Wilson
Journal:  Cardiovasc Res       Date:  1978-11       Impact factor: 10.787

5.  Ca2+-dependent tension generation in chemically 'skinned' cardiac trabeculae: effect of pH [proceedings].

Authors:  J C Kentish; W G Nayler
Journal:  J Physiol       Date:  1978-11       Impact factor: 5.182

6.  Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

Authors:  D P Zipes; J C Fischer
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

7.  Existence and role of a slow inward current during the frog atrial action potential.

Authors:  O Rougier; G Vassort; D Garnier; Y M Gargouil; E Coraboeuf
Journal:  Pflugers Arch       Date:  1969       Impact factor: 3.657

8.  Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs.

Authors:  K A Reimer; J E Lowe; R B Jennings
Journal:  Circulation       Date:  1977-04       Impact factor: 29.690

9.  Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.

Authors:  P D Henry; R Shuchleib; L J Borda; R Roberts; J R Williamson; B E Sobel
Journal:  Circ Res       Date:  1978-09       Impact factor: 17.367

10.  Electrophysiologic effects of diltiazem, a new slow channel inhibitor, on canine cardiac fibers.

Authors:  T Saikawa; Y Nagamoto; M Arita
Journal:  Jpn Heart J       Date:  1977-03
View more
  18 in total

1.  Studies on the calcium antagonistic action of tetrandrine: XIV. Influence of tetrandrine and verapamil on hemodynamic action of ouabain in guinea pigs.

Authors:  W X Yao; G J Xia; D C Fang; M X Jiang
Journal:  J Tongji Med Univ       Date:  1987

Review 2.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

3.  Studies on the calcium antagonistic action of tetrandrine: IV. Effects of tetrandrine on isoproterenol and calcium-mediated positive chronotropic action in isolated rabbit atria.

Authors:  D C Fang; W X Yao; G J Xia; M X Jiang
Journal:  Acta Acad Med Wuhan       Date:  1984

4.  The acute effects of nifedipine on red cell deformability in angina pectoris.

Authors:  D G Waller; H P Nicholson; S Roath
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

Review 5.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

6.  Neuromuscular blocking action of verapamil in cats.

Authors:  B J Kraynack; N W Lawson; J Gintautas
Journal:  Can Anaesth Soc J       Date:  1983-05

7.  Studies on the calcium antagonistic action of tetrandrine: VII. Effects of tetrandrine on contractility of isolated rat uterus.

Authors:  D C Fang; W X Yao; J L Zhao; M X Jiang
Journal:  Acta Acad Med Wuhan       Date:  1984

8.  Direct inhibitory effects of some 'calcium-antagonists' and trifluoperazine on the contractile proteins in smooth muscle.

Authors:  M Spedding
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

9.  Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.

Authors:  B Larsson; E D Högestätt; A Mattiasson; K E Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

Review 10.  Calcium antagonists. Pharmacodynamic effects and mechanism of action.

Authors:  T T Zsotér; J G Church
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.